<p>Bahl &amp; Gaynor Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在强生（NYSE:JNJ - 免费报告）股票的持有量提高了 15.5%。该机构投资者在此期间购买了额外的 338,839 股后，持有该公司 2,526,930 股股票。强生约占 Bahl &amp; Gaynor Inc.投资组合的 2.0%，使其成为该公司第 12 大持股。截止最近一个季度末，Bahl &amp; Gaynor Inc.持有的强生股份约占 0.10%，价值 3.85989 亿美元。</p>
<p>获取 <strong>强生</strong> 的提醒：</p>
<ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
<p>其他一些机构投资者最近也对 JNJ 的持仓进行了调整。GFG Capital LLC 在第二季度购买了价值约 35,000 美元的强生新股份。Stone House Investment Management LLC 在第一季度获得了价值约 47,000 美元的强生新股份。1248 Management LLC 在第一季度购买了价值约 48,000 美元的强生新股份。Harvest Fund Management Co. Ltd 在第一季度获得了价值约 52,000 美元的强生新股份。最后，Pandora Wealth Inc.在第一季度购买了价值约 65,000 美元的强生新股份。机构投资者和对冲基金持有该公司 69.55% 的股票。</p>
<h2>强生股票表现</h2>
<p>强生股票在周五开盘价为 203.88 美元。强生的 52 周低点为 140.68 美元，52 周高点为 206.94 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务股本比率为 0.50。该股票的市值为 4912.1 亿美元，市盈率为 19.68，市盈增长比率为 2.19，贝塔值为 0.38。该公司的 50 日简单移动平均线为 188.25 美元，200 日简单移动平均线为 171.55 美元。</p>
<ul>
<li>3 只适合不安市场的聪明防御性股票</li>
</ul>
<p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日（星期三）公布了季度财报。公司报告每股收益为 2.26 美元。强生的股本回报率为 32.73%，净利润率为 27.26%。该季度的收入为 240.2 亿美元。分析师平均预计强生在当前年度的每股收益为 10.58 美元。</p>
<h2>强生股息公告</h2>
<p>该公司最近还宣布了一项季度股息，将于 12 月 9 日（星期二）支付。11 月 25 日（星期二）登记的投资者将获得 1.30 美元的股息。这代表着每年 5.20 美元的股息和 2.6% 的股息收益率。除息日期为 11 月 25 日（星期二）。强生的派息比率目前为 50.19%。</p>
<h2>内部买卖</h2>
<ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
<p>在相关消息中，执行副总裁 Jennifer L. Taubert 在 9 月 4 日（星期四）以 177.81 美元的平均价格出售了 56,471 股公司的股票，总交易额为 10,041,108.51 美元。出售后，该执行副总裁在公司持有 178,013 股，价值约 31,652,491.53 美元。这笔交易代表着其持股减少了 24.08%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。公司内部人士持有该公司 0.16% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>多位研究分析师对该股票发布了报告。Scotiabank 在 11 月 13 日（星期四）对强生股票进行了覆盖，给予了 “行业表现优于大盘” 的评级，并设定了 230.00 美元的目标价。Cowen 在 10 月 14 日（星期二）的研究报告中重申了对强生股票的 “买入” 评级。摩根士丹利在 10 月 15 日（星期三）的研究报告中设定了 190.00 美元的目标价。Wall Street Zen 在 9 月 13 日（星期六）的研究报告中将强生的评级从 “持有” 上调至 “买入”。最后，Guggenheim 在 9 月 23 日（星期二）的研究报告中将强生的评级从 “中性” 上调至 “买入”，并将其目标价从 167.00 美元上调至 206.00 美元。四位研究分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，平均目标价为 201.05 美元。</p>
<p><strong>查看我们关于 JNJ 的最新报告</strong></p>
<h2>关于强生</h2>
<p>（免费报告）</p>
<p>强生是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>3 只引领迷因股票复苏的股票</li>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>什么是欧元区 STOXX 50 指数？</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在强生吗？</h2>
<p>在考虑强生之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
<p>尽管强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

强生

<p>Bahl & Gaynor Inc. 在第二季度将其在强生的持股增加了 15.5%，目前拥有 2,526,930 股，价值 3.8599 亿美元。这使得强生占他们投资组合的 2.0%，是他们第 12 大持股。其他机构投资者也对其强生的持仓进行了调整。强生的股票开盘价为 203.88 美元，市值为 4912.1 亿美元。该公司报告第二季度每股收益为 2.26 美元，并宣布每股季度分红为 1.30 美元。几位分析师对强生给予了买入评级</p>

<p>Bahl &amp; Gaynor Inc. raised its holdings in shares of Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 15.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,526,930 shares of the company's stock after purchasing an additional 338,839 shares during the period. Johnson &amp; Johnson accounts for approximately 2.0% of Bahl &amp; Gaynor Inc.'s investment portfolio, making the stock its 12th biggest holding. Bahl &amp; Gaynor Inc. owned about 0.10% of Johnson &amp; Johnson worth $385,989,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Bahl &amp; Gaynor Inc. 在最近向证券交易委员会的披露中表示，在第二季度将其在强生（NYSE:JNJ - 免费报告）股票的持有量提高了 15.5%。该机构投资者在此期间购买了额外的 338,839 股后，持有该公司 2,526,930 股股票。强生约占 Bahl &amp; Gaynor Inc.投资组合的 2.0%，使其成为该公司第 12 大持股。截止最近一个季度末，Bahl &amp; Gaynor Inc.持有的强生股份约占 0.10%，价值 3.85989 亿美元。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>强生</strong> 的提醒：</p>
</div><ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
</div><p>A number of other institutional investors have also recently made changes to their positions in JNJ. GFG Capital LLC purchased a new stake in Johnson &amp; Johnson in the second quarter valued at about $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson &amp; Johnson during the first quarter valued at about $47,000. 1248 Management LLC purchased a new position in shares of Johnson &amp; Johnson in the 1st quarter valued at approximately $48,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson &amp; Johnson in the 1st quarter worth approximately $52,000. Finally, Pandora Wealth Inc. purchased a new stake in Johnson &amp; Johnson during the 1st quarter worth approximately $65,000. Institutional investors and hedge funds own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也对 JNJ 的持仓进行了调整。GFG Capital LLC 在第二季度购买了价值约 35,000 美元的强生新股份。Stone House Investment Management LLC 在第一季度获得了价值约 47,000 美元的强生新股份。1248 Management LLC 在第一季度购买了价值约 48,000 美元的强生新股份。Harvest Fund Management Co. Ltd 在第一季度获得了价值约 52,000 美元的强生新股份。最后，Pandora Wealth Inc.在第一季度购买了价值约 65,000 美元的强生新股份。机构投资者和对冲基金持有该公司 69.55% 的股票。</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>强生股票表现</h2>
</div><p>Shares of JNJ stock opened at $203.88 on Friday. Johnson &amp; Johnson has a 52-week low of $140.68 and a 52-week high of $206.94. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The business has a 50-day simple moving average of $188.25 and a 200-day simple moving average of $171.55.</p>
<div class="lb-trans"><p>强生股票在周五开盘价为 203.88 美元。强生的 52 周低点为 140.68 美元，52 周高点为 206.94 美元。该公司的速动比率为 0.80，流动比率为 1.07，债务股本比率为 0.50。该股票的市值为 4912.1 亿美元，市盈率为 19.68，市盈增长比率为 2.19，贝塔值为 0.38。该公司的 50 日简单移动平均线为 188.25 美元，200 日简单移动平均线为 171.55 美元。</p>
</div><ul>
<li>3 Smart Defensive Stocks for an Uneasy Market</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只适合不安市场的聪明防御性股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. On average, equities analysts expect that Johnson &amp; Johnson will post 10.58 EPS for the current year.</p>
<div class="lb-trans"><p>强生（NYSE:JNJ - 获取免费报告）最近在 8 月 30 日（星期三）公布了季度财报。公司报告每股收益为 2.26 美元。强生的股本回报率为 32.73%，净利润率为 27.26%。该季度的收入为 240.2 亿美元。分析师平均预计强生在当前年度的每股收益为 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Dividend Announcement</h2>
<div class="lb-trans"><h2>强生股息公告</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson &amp; Johnson's payout ratio is currently 50.19%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 12 月 9 日（星期二）支付。11 月 25 日（星期二）登记的投资者将获得 1.30 美元的股息。这代表着每年 5.20 美元的股息和 2.6% 的股息收益率。除息日期为 11 月 25 日（星期二）。强生的派息比率目前为 50.19%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li>
</ul>
<div class="lb-trans"><ul>
<li>持有评级，高回报？3 只可能超出预期的股票</li>
</ul>
</div><p>In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，执行副总裁 Jennifer L. Taubert 在 9 月 4 日（星期四）以 177.81 美元的平均价格出售了 56,471 股公司的股票，总交易额为 10,041,108.51 美元。出售后，该执行副总裁在公司持有 178,013 股，价值约 31,652,491.53 美元。这笔交易代表着其持股减少了 24.08%。该交易已在向证券交易委员会的备案中披露，相关信息可通过此链接访问。公司内部人士持有该公司 0.16% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of research analysts have issued reports on the stock. Scotiabank assumed coverage on shares of Johnson &amp; Johnson in a report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $230.00 price target for the company. Cowen restated a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research note on Tuesday, October 14th. Morgan Stanley set a $190.00 price target on Johnson &amp; Johnson in a research note on Wednesday, October 15th. Wall Street Zen upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, September 13th. Finally, Guggenheim upgraded Johnson &amp; Johnson from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and upped their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Four research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $201.05.</p>
<div class="lb-trans"><p>多位研究分析师对该股票发布了报告。Scotiabank 在 11 月 13 日（星期四）对强生股票进行了覆盖，给予了 “行业表现优于大盘” 的评级，并设定了 230.00 美元的目标价。Cowen 在 10 月 14 日（星期二）的研究报告中重申了对强生股票的 “买入” 评级。摩根士丹利在 10 月 15 日（星期三）的研究报告中设定了 190.00 美元的目标价。Wall Street Zen 在 9 月 13 日（星期六）的研究报告中将强生的评级从 “持有” 上调至 “买入”。最后，Guggenheim 在 9 月 23 日（星期二）的研究报告中将强生的评级从 “中性” 上调至 “买入”，并将其目标价从 167.00 美元上调至 206.00 美元。四位研究分析师给予该股票 “强烈买入” 评级，十三位给予 “买入” 评级，九位给予 “持有” 评级。根据 MarketBeat，该股票的平均评级为 “适度买入”，平均目标价为 201.05 美元。</p>
</div><p><strong>Check Out Our Latest Report on JNJ</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 JNJ 的最新报告</strong></p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>关于强生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>强生是一家控股公司，专注于医疗领域的产品研究、开发、生产和销售。它通过创新药物和医疗技术两个部门运营。创新药物部门专注于免疫学、传染病、神经科学、肿瘤学、心血管和代谢以及肺动脉高压。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li>
<li>What is the Euro STOXX 50 Index?</li>
<li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过强生</li>
<li>3 只引领迷因股票复苏的股票</li>
<li>一项宏伟的人工智能投资？Stanley Druckenmiller 的最新科技动态</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>12 位分析师刚刚提高了 CrowdStrike 的目标——他们预见了什么</li>
<li>什么是欧元区 STOXX 50 指数？</li>
<li>Palo Alto Networks 股票刚刚回调——这是一个理想的买入区吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在强生吗？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑强生之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而强生并不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管强生目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bahl & Gaynor Inc. 购买了强生 $JNJ 的股票